Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,888 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: no drug Clear all
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 12, 2026, 7:52 AM EDT
Recruiting No phase listed Observational

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

NCT05853783
View directory record Official record
Conditions
Mouth Diseases
Interventions
STRATICYTE™ Test
Other
Lead sponsor
Proteocyte Diagnostics Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Loma Linda, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 12, 2026, 7:52 AM EDT
Not listed Phase 3 Interventional

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

NCT00246727
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Selected Vegetable and Herb Mix
Drug
Lead sponsor
Sun Farm Corporation
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Recovery Management Checkups for Primary Care Experiment

NCT03746756
View directory record Official record
Conditions
Substance Use Disorders
Interventions
SBIRT, SBIRT+RMC-PC
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Chicago, Illinois • Lansing, Illinois • Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 2 Interventional

Prolonged Daily Temozolomide for Low-Grade Glioma

NCT00165360
View directory record Official record
Conditions
Glioma, Astrocytoma, Oligodendroglioma
Interventions
Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423
View directory record Official record
Conditions
Nicotine Addiction, Panic Attack
Interventions
d-cycloserine, Pill Placebo, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
Drug · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 12, 2026, 7:52 AM EDT
Terminated Phase 2 Interventional

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

NCT06032546
View directory record Official record
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Interventions
Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Bevacizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

NCT02742441
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
122-0551 Foam, Vehicle Foam
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
21
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Encino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 12, 2026, 7:52 AM EDT
Terminated No phase listed Observational

Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome

NCT02288702
View directory record Official record
Conditions
Down Syndrome
Interventions
monitoring BIS in both groups
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Pain and Medication Use Following Surgery

NCT03179566
View directory record Official record
Conditions
Opioid Use
Interventions
Information Sheet, Deterra Drug Deactivation System
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm

NCT04758637
View directory record Official record
Conditions
Opioid Abuse
Interventions
Overdose Notification
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 12, 2026, 7:52 AM EDT
Terminated No phase listed Observational

Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

NCT03471481
View directory record Official record
Conditions
Epilepsy, Magnesium Deficiency, Vitamin D Deficiency
Interventions
No Intervention. Study is Cross Sectional in nature
Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 12, 2026, 7:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT01577628
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions
Lipikar Balm AP
Drug
Lead sponsor
Cosmetique Active International
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Canton, Michigan • Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 4 Interventional Results available

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

NCT00282828
View directory record Official record
Conditions
Social Phobia
Interventions
Sertraline, Venlafaxine, Placebo, Clonazepam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
La Jolla, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 12, 2026, 7:52 AM EDT
Terminated No phase listed Observational

PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease

NCT05031520
View directory record Official record
Conditions
Non-Obstructive Coronary Atherosclerosis
Interventions
Coronary computed tomography angiography (CCTA), Isovue, Nitroglycerin, Metoprolol
Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 4 Interventional Results available

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

NCT01018056
View directory record Official record
Conditions
Tourette Syndrome
Interventions
D-serine, Riluzole, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 12, 2026, 7:52 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

NCT03015623
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SBI-101, Sham
Biological · Device
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Telephone Counseling for Tobacco Cessation

NCT01489579
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Telephone Counseling for Tobacco Cessation, Usual Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Study for Development of an Early Test for Ovarian Failure

NCT00006156
View directory record Official record
Conditions
Healthy, Premature Ovarian Failure
Interventions
Control, Drug: FSH
Other · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 12, 2026, 7:52 AM EDT
Not listed Not applicable Interventional

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

NCT06304207
View directory record Official record
Conditions
Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD, Chronic Lung Disease, Pulmonary Fibrosis, Interstitial Lung Disease, Bronchiectasis, Chronic Asthma, Chronic Asthmatic Bronchitis
Interventions
Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
Combination Product
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 12, 2026, 7:52 AM EDT
Completed Not applicable Interventional

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

NCT00552500
View directory record Official record
Conditions
Insulin Resistance, Body Composition
Interventions
Depakote (valproate)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 12, 2026, 7:52 AM EDT